Lunai Bioworks, Inc. LNAI 深 滬
已收盤 02-06 16:00:00 美东时间
0.6624
+0.016
+2.40%
華盛通- 最 高0.6981
- 今 開0.6534
- 成交量 15.70万股
- 最 低 0.63
- 昨 收 0.6469
- 總市值 1552.05万
- 52周最高 1.66
- 市盈率 靜 --
- 換手率 0.67%
- 52周最低 0.1214
- 委 比 -33.33%
- 總股本 2343.07万
- 歷史最高 13.78
- 量 比 1.68
- 振 幅 10.53%
- 歷史最低 0.1214
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
AI Platform Achieves Key Milestones, Triggering Launch of Alcohol Use Disorder Program SACRAMENTO, Calif. , Jan. 26, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug di...
01-26 22:30
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance
AI-powered drug discovery and biodefense company engages pharma on CNS programs amid rising deal activity SACRAMENTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Lunai Bioworks Inc. (NASDAQ: LNAI)...
2025-12-18 22:00
Lunai Bioworks Identifies Three Parkinson's Disease Subtypes And Drug Targets To Accelerate Therapeutic Development In $13B Market
Lunai Bioworks (NASDAQ:LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three clinically relevant Parkinson's disease subtypes and prioritized drug
2025-12-09 20:50
Lunai Bioworks Secures First Letter Of Intent For Its Immune Cell Therapy
Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, which achieved
2025-11-25 20:46
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Kazia Therapeutics (NASDAQ:KZIA) shares increased by 51.6% to $8.73 du...
2025-11-19 20:05
Lunai Bioworks Announces Early Results From AI-Based Platform Designed To Identify Compounds That Interact With Acetylcholinesterase, Same Molecular Target Affected By Nerve Agents
In the face of growing global concern over the potential use of chemical weapons such as the nerve agent Sarin, Lunai Bioworks Inc. (NASDAQ:LNAI) today announced promising early results from its AI-based platform
2025-10-30 21:33
Lunai Bioworks Says Nature Communications Study Identifies Prognostic Biomarkers For Duchenne Muscular Dystrophy Using SomaScan; Lunai Bioworks' BioSymetrics Leads Multi-Institutional Team With Leiden University And University Of Florida
Published in Nature Communications, a new study uncovers critical protein biomarkers that predict functional decline in Duchenne Muscular Dystrophy (DMD), opening doors to more personalized care and improved clinical
2025-10-16 21:51
Lunai Bioworks Reports 35% Improvement In Alzheimer's Diagnostic Accuracy Via Augusta AI; Launches Preclinical Program For Early Intervention
Lunai Bioworks (NASDAQ:LNAI) today announced a major advance in Alzheimer's research: its AI platform, Augusta™, achieved up to a 35% improvement in diagnostic accuracy by combining MRI scans with genetic and
2025-10-06 21:18
